首页> 美国卫生研究院文献>Elsevier Sponsored Documents >A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA
【2h】

A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA

机译:底物模拟物允许高通量测定FabA蛋白因此可鉴定铜绿假单胞菌FabA的新型抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathways that comprise iterative chain elongation, reduction, and dehydration reactions. The bacterial FASII pathway differs significantly from human FAS pathways and is a long-standing target for antibiotic development against Gram-negative bacteria due to differences from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes. N-Acetylcysteamine (NAC) fatty acid thioesters have been used as mimics of the natural acyl carrier protein pathway intermediates to assay FASII enzymes, and we now report an assay of FabV from Pseudomonas aeruginosa using (E)-2-decenoyl-NAC. In addition, we have converted an existing UV absorbance assay for FabA, the bifunctional dehydration/epimerization enzyme and key target in the FASII pathway, into a high-throughput enzyme coupled fluorescence assay that has been employed to screen a library of diverse small molecules. With this approach, N-(4-chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine (N42FTA) was found to competitively inhibit (pIC50 = 5.7 ± 0.2) the processing of 3-hydroxydecanoyl-NAC by P. aeruginosa FabA. N42FTA was shown to be potent in blocking crosslinking of Escherichia coli acyl carrier protein and FabA, a direct mimic of the biological process. The co-complex structure of N42FTA with P. aeruginosa FabA protein rationalises affinity and suggests future design opportunities. Employing NAC fatty acid mimics to develop further high-throughput assays for individual enzymes in the FASII pathway should aid in the discovery of new antimicrobials.
机译:真核生物和原核生物具有脂肪酸合酶(FAS)生物合成途径,包括迭代链延长,还原和脱水反应。细菌FASII途径与人FAS途径有显着不同,由于与人FAS的差异,细菌FASII途径是针对革兰氏阴性细菌的抗生素开发的长期目标,并且已知几种现有的抗菌剂可抑制FASII酶。 N-乙酰半胱胺(NAC)脂肪酸硫酯已被用作模拟天然酰基载体蛋白途径中间体的方法来测定FASII酶,现在我们报道使用(E)-2-癸烯酰-NAC对铜绿假单胞菌的FabV进行测定。此外,我们已将FabA,双功能脱水/表位化酶和FASII途径中的关键靶点的现有UV吸收测定法转换为高通量酶联荧光测定法,该方法已用于筛选各种小分子文库。通过这种方法,发现N-(4-氯苄基)-3-(2-呋喃基)-1H-1,2,4-三唑-5-胺(N42FTA)具有竞争性抑制作用(pIC50 = 5.7±0.2)铜绿假单胞菌FabA制备3-羟基癸酰-NAC。 N42FTA被证明可有效阻止大肠杆菌酰基载体蛋白和FabA的交联,这是生物学过程的直接模拟。 N42FTA与铜绿假单胞菌FabA蛋白的共复杂结构合理化了亲和力,并提出了未来的设计机会。利用NAC脂肪酸模拟物为FASII途径中的单个酶开发进一步的高通量测定方法,应有助于发现新的抗菌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号